Pembrolizumab biosimilar(Formycon)

帕博利珠单抗生物类似药（Formycon）

Report date: 2026/02/14 20:00:22

Base Information

Drug NamePembrolizumab biosimilar(Formycon)
Drug Alias NameFYB-206
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionProgrammed cell death protein 1 inhibitors
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTurkeyGeorgia +[4] 
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFormycon AG
China Registration ClassN/A

Develop Information

Active CompaniesFormycon AG
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A